Daily oral edaravone (Radicava ORS) was not superior to the FDA-approved on/off regimen in amyotrophic lateral sclerosis (ALS ...

胶质母细胞瘤是侵袭性脑肿瘤，中位生存期仍不到22个月。FDA批准的ALS药物Edaravone能抑制iNOS信号，而iNOS信号是脑肿瘤干细胞的关键调节因子。基于此，加拿大研究人员发现Edaravone在临床前模型的治疗延迟了胶质母细胞瘤的发生，并延长临床前模型的寿命 ...

Research provides evidence that a drug used to slow the progression of the disease ALS shows promise in suppressing the self-renewing cancerous stem cells that challenge the present standards of care ...

刚刚，国家药监局官网显示，渤健（Biogen）药物托夫生（Tofersen）在国内获批上市，用于治疗 SOD1 基因突变的成人肌萎缩侧索硬化症 （ALS），即渐冻症。

Glioblastomas are aggressive brain tumors with a median survival time of less than 22 months despite standard therapy including surgery, irradiation, and chemotherapy.

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the presentation of real-world data from a retrospective analysis of healthcare resource utilization (HCRU) among people with amyotrophic ...

The presentations will provide insights into patient demographics, treatment duration, progression milestones and healthcare resource utilization data among RADICAVA ORS ® (edaravone)-treated ...